Women First Weight Loss & Lipo Center (Chesapeake, Virginia)

Clinic Introduction

Women First Weight Loss & Lipo Center in Chesapeake, Virginia, operates under the clinical oversight of Ongo Weight Loss, delivering medically supervised weight management programs that combine FDA-approved GLP-1 receptor agonist medications with structured lifestyle interventions. The clinic holds LegitScript certification, an independent verification standard that confirms compliance with healthcare regulations and ethical prescribing practices for telehealth weight loss services. This certification provides patients in Chesapeake and throughout Virginia with assurance that their treatment protocols meet rigorous safety and transparency benchmarks in an industry where regulatory oversight varies widely. The clinic's pharmacological approach centers on three GLP-1 medications proven to reduce appetite and improve glycemic control: tirzepatide, a dual GIP/GLP-1 receptor agonist approved for chronic weight management and type 2 diabetes; semaglutide, a once-weekly injectable that mimics incretin hormones to enhance satiety and slow gastric emptying; and liraglutide, a daily GLP-1 analog used for both weight reduction and diabetes care. Each medication is prescribed based on individual metabolic profiles, weight loss goals, and comorbid conditions such as prediabetes or insulin resistance. Patients receive detailed injection training, dosage titration schedules, and monitoring protocols to minimize gastrointestinal side effects while optimizing therapeutic outcomes. The clinic's dual focus on weight management and diabetes care allows providers to address the interconnected metabolic dysfunction that often underlies both conditions, particularly in patients with elevated HbA1c levels or metabolic syndrome. Ongo Weight Loss brings a structured clinical framework to Women First Weight Loss & Lipo Center, emphasizing evidence-based prescribing and continuous patient monitoring throughout treatment. Providers conduct comprehensive intake assessments that include medical history review, current medication reconciliation, and evaluation of contraindications such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The telehealth model enables patients across Chesapeake, Virginia Beach, Norfolk, and surrounding Hampton Roads communities to access specialist-level weight management care without geographic barriers. Virtual consultations include review of home-monitored metrics such as weekly weight trends, blood glucose readings for diabetic patients, and symptom tracking to adjust medication dosages or address emerging concerns promptly. Patients beginning treatment at Women First Weight Loss & Lipo Center typically start with an initial telehealth consultation to establish candidacy for GLP-1 therapy, followed by baseline laboratory work ordered through local Chesapeake-area facilities to assess renal function, liver enzymes, and thyroid markers. Medication is prescribed through partner pharmacies with home delivery options, and patients receive detailed administration guides covering injection technique, proper refrigeration, and needle disposal. Follow-up appointments occur at regular intervals—often every four weeks during the titration phase—to evaluate weight loss progress, review tolerance to the medication, and modify treatment plans as needed. The clinic provides guidance on nutrition strategies that complement GLP-1 therapy, such as prioritizing protein intake to preserve lean muscle mass during caloric restriction and managing the reduced appetite these medications produce. Patients with diabetes receive coordinated care that includes monitoring for hypoglycemia risk, particularly when GLP-1 medications are used alongside insulin or sulfonylureas. With a 4.9-star Google rating based on 51 reviews, Women First Weight Loss & Lipo Center has established a reputation in the Chesapeake medical community, with patient feedback frequently referencing the broader women's health services associated with the practice. The telehealth delivery model addresses a critical access gap for working professionals and parents in the Hampton Roads region who require flexible scheduling and eliminate commute time to brick-and-mortar facilities. LegitScript certification further distinguishes the clinic in a telehealth landscape where patients must navigate varying levels of clinical rigor and prescriber qualifications. For Virginia residents seeking medically supervised weight loss with prescription GLP-1 medications and concurrent diabetes management, Women First Weight Loss & Lipo Center provides a regulated, protocol-driven option that integrates pharmacotherapy with metabolic health optimization. The scope of services recorded for this clinic covers testosterone optimization for men experiencing low energy, reduced libido, changes in body composition, or sleep and mood shifts; medically supervised weight management, pairing prescription options with nutrition and lifestyle guidance rather than prescription alone. Practical details recorded for this location: the phone number on file is (757) 548-2800; the published hours are Friday: 9 AM-3:30 PM; Monday: Closed; Sunday: Closed; Tuesday: 11 AM-5:30 PM; Saturday: Closed; Thursday: 9 AM-3:30 PM; Wednesday: 9 AM-3:30 PM; the clinic website on file is https://ongoweightloss.com. Patients travelling to Chesapeake should confirm hours before a trip, because appointment times and operating schedules differ between locations in a multi-site practice. This entry covers the Chesapeake location. Hormone and peptide therapy is a medical decision that should follow an evaluation and a discussion with a qualified clinician. Results vary between individuals, and no outcome is guaranteed. This profile is informational and does not replace medical advice.